Protara

Proteon was originally focused on developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. Its lead product, however, a recombinant human elastase, failed in late-stage trials designed test its ability to prolong the patency and reduce the failure of haemodialysis vascular access in patients with chronic kidney disease. The company had gone public in October 2014, and merged with ArTara Therapeutics in 2019 to form Protara Therapeutics (NASDAQ CM: TARA).